Literature DB >> 12456791

A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.

Alaina J James1, Irina U Agoulnik, Jonathan M Harris, Grant Buchanan, Wayne D Tilley, Marco Marcelli, Dolores J Lamb, Nancy L Weigel.   

Abstract

Functional analysis of androgen receptor (AR) gene mutations isolated from prostate cancer has led to the identification of residues that play important roles in the structure and function of the receptor. Here we report the characteristics of a novel AR mutation A748T located in helix 5 of the ligand-binding domain, which was identified in metastatic prostate cancer. Despite a normal hormone-binding affinity, A748T causes hormone concentration-dependent defects in nuclear accumulation and transcriptional activation. Moreover, when equivalent amounts of DNA are transfected, the mutant is expressed at much lower levels than the wild-type AR (ARWT). Treatment with geldanamycin to disrupt receptor-heat shock protein complexes rapidly decreases the levels of ARWT but not A748T, suggesting that the lower expression and rapid degradation rate of A748T is due to weaker interactions with heat shock proteins. Further analysis revealed that hormone dissociates from A748T five times faster than from ARWT. Loss of the ability to form stable amino/carboxyl-terminal interactions causes accelerated dissociation rates in some AR mutants. However, A748T exhibits normal amino/carboxyl-terminal interactions at high hormone concentrations, suggesting that the mutation alters interactions with ligand. Consistent with this conclusion, our structural model predicts that A748T disrupts crucial contact points with ligand, thereby altering the conformation of the ligand-binding domain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12456791     DOI: 10.1210/me.2001-0281

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  4 in total

1.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

2.  Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Authors:  Ayesha A Shafi; Marc B Cox; Nancy L Weigel
Journal:  Steroids       Date:  2013-02-01       Impact factor: 2.668

3.  Profiling human androgen receptor mutations reveals treatment effects in a mouse model of prostate cancer.

Authors:  Orla A O'Mahony; Mara P Steinkamp; Megan A Albertelli; Michele Brogley; Haniya Rehman; Diane M Robins
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

4.  Simulating androgen receptor selection in designer yeast.

Authors:  Haoran Zhang; Lu Zhang; Yipeng Xu; Shaoyong Chen; Zhenyi Ma; Mingdong Yao; Fangyin Li; Bo Li; Yingjin Yuan
Journal:  Synth Syst Biotechnol       Date:  2022-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.